Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Fumigant 93 × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Plasma cell 1 Lymphoid 1 Gastrointestinal 1 Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1036 Cisplatin 803 Pemetrexed 745 pembrolizumab 552 Paclitaxel 534 Docetaxel 482 Gemcitabine 370 Radiotherapy 352 Erlotinib Hydrochloride 344 Bevacizumab 304 Nivolumab 301 Etoposide 264 durvalumab 245 Drug Therapy 224 osimertinib 206 atezolizumab 196 Radiosurgery 167 Gefitinib 164 Vinorelbine 134 Magnetic Resonance Spectroscopy 121 Ipilimumab 110 130-nm albumin-bound paclitaxel 110 Cetuximab 98 Topotecan 93 Specimen Handling 91 Cyclophosphamide 91 Surgical Procedures, Operative 90 tislelizumab 88 Blood Specimen Collection 88 Taxes 87

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02504489 2022-09-10

DUBLIN-3

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡